← All trials
NCT07073768
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2025
- Primary completion
- Dec 26, 2026
- Completion date
- Dec 30, 2026
- First posted
- Jul 18, 2025
- Last posted
- Jul 18, 2025
- Enrollment
- 126
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Khyber Medical University PeshawarLead sponsor
- Khyber Medical University PeshawarSponsor investigator
- Khyber Medical University PeshawerOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.